Effect of onabotulinumtoxinA on patient-related outcomes for lower limb spasticity  by Wein, T. et al.
e46 Spasticity / Annals of Physical and Rehabilitation Medicine 57S (2014) e42–e52
sic + hypnosis) and the group “witness” (standards analgesic). The patients gave
their agreement to participate in the study and participate in the choices of the
analgesic methods. The evaluation was performed at the end of the session and
during follow-up.
Results.– Certain are in progress: anxiety, pain felt during the injection, and
reactivity to needle seems better in the group hypnosis. The comfort of the
practitioner is globally improved, function of its experience in hypnosis
Conclusions.– Hypnosis has its place in our practice concerning the pains cause
by interventions, which is common in PRM practice. It requires one, however,
one unwound by the different care including information around the hypnosis
and an induction of the latter. Profits with regard to these arrangements are
discussed.
http://dx.doi.org/10.1016/j.rehab.2014.03.163
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Background.– Spasticity is a disabling consequence of stroke and traumatic
brain injury and contributes to other conditions, such as pain, impairment in
daily activities and gait. OnabotulinumtoxinA has been shown to reduce muscle
tone in patients with lower limb spasticity (LLS). We sought to assess whether
reducing muscle tone is associated with clinically meaningful improvements in
patient-related outcomes.
Methods.– Data from 3 published placebo-controlled LLS trials
(AGN/HO/SPA/001-191622 (BOTOX Economic Spasticity Trial [BEST]),
BTOX-702-8051, BTX108512) using onabotulinumtoxinA and the Patient
Registry Outcomes in Spasticity (PROS) World registry were indirectly
compared for patient-related outcomes.
Results.– A total of 509 patients were identified with LLS involving the ankle.
The patient clinical global impression scale was significantly* correlated with
modified Ashworth scale scores in BTX108512. Eighty percent of patients in
PROS were satisfied with their injections. BEST was significant* for the pro-
portion of patients reporting 50% reduction in pain. Significant* improvements
in spasms, cramps, and patient-rated injection benefit were demonstrated in
BTOX-702-8051 with strong trends in gait speed. Functional goal attainment
was significant* in BEST with improvements in PROS.
Conclusions.– Reductions in muscle tone after onabotulinumtoxinA treatment
are beneficial to patients as demonstrated by improvement in patient-related
outcomes.
*P < 0.05 vs placebo for ≥ 1 post-treatment time point.
http://dx.doi.org/10.1016/j.rehab.2014.03.164
P205-e
Development of a picture guide to identify
common postures of spasticity
I. Odderson a, T. Bentley b, J. Wissel c, K. Dashtipour d,
N. Johnson e, C. Evans e, P. Gillard f,∗, R. Zorowitz g
a University of Washington, Seattle, WA, USA
b McMaster University, Hamilton, Ontario, Canada
c Neurological Rehabilitation, Department of Neurology, Vivantes Klinikum
Spandau, Berlin, Germany
d Department of Neurology, Loma Linda University School of Medicine, Loma
Linda, CA, USA
e Endpoint Outcomes, Boston, MA, USA
f Global Health Outcomes Strategy and Research, Allergan, Inc, Irvine, CA,
USA
g The Johns Hopkins University, Baltimore, MD, USA
∗Corresponding author.
Keywords: Spasticity; Patient reported outcome; Clinician reported outcome
Background.– An illustrative picture guide to identify common postures of upper
and lower limb spasticity was developed for use by clinicians and patients.
Methods.– Five specialists in spasticity managment provided guidance on the
most common postures observed in patients with spasticity. A photo shoot with
patients was held to capture photos of these spasticity postures across four etio-
logies (stroke, traumatic brain injury, multiple sclerosis, and cerebral palsy).
Initially, clinicians separately ranked the most representative photo for each
posture. Subsequently, the group reached a consensus on the best photo for each
posture. A medical illustrator converted the posture photos into representative
sketches for inclusion into the picture tool.
Results.– Fifteen patients with spasticity representing each etiology participated
in the photo shoot. All postures were photographed from various angles, resul-
ting in at least five unique photos per posture. Fifteen common postures were
identified and converted into representative sketches.
Conclusions.– The spasticity common postures guide will be a useful tool
for determining the prevalence of spasticity postures and gaining a better
understanding of the treatment goals of spasticity presentations. Additio-
nally, the guide may reduce the heterogeneity of spasticity evaluation among
clinicans. Patients’ understanding of the guide will be evaluated in future inter-
views.
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Background.– Botulinum toxin (BoNT) injections are first-line treatment for
post-stroke spasticity (PSS). However, some patients may experience re-
emergence of symptoms before re-injection with a standard 12-weekly injection
regimen.
Methods.– Structured patient and physician surveys in Canada, France, Ger-
many, and USA. Patients had received ≥ 2 BoNT-A treatments for PSS.
Physicians had ≥ 3 years’ experience injecting BoNT for PSS. Information
regarding treatment satisfaction was collected from both groups.
Results.– Sixty-one of 79 patients (77%) received onabotulinumtoxinA, 15/79
(19%) abobotulinumtoxinA and 3/79 (4%) incobotulinumtoxinA. Most patients
were very (40.5%) or somewhat (48.1%) satisfied with BoNT treatment. Satis-
faction was highest at time of peak effect and lowest before re-injection. Injection
intervals ≤ 12 or ≤ 10 weeks were preferred by 78.9% or 43.4% of patients, and
received by 45.6% or 6.3%, respectively. Mean (standard deviation) injection
interval received was 13.7 (3.5) weeks. Physicians (n = 105) were modera-
tely (57.7%) or very (36.5%) satisfied with treatment, but felt that 16.2%
or 24.6% of patients would benefit from shorter intervals or higher doses,
respectively.
Conclusions.– Patient and physician satisfaction with BoNT treatment for PSS
is high, although patient preference is for shorter injection intervals. Physicians
believe shorter intervals and higher doses may confer additional benefit in some
patients.
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